Correction: End-ischemic hypothermic oxygenated perfusion for extended criteria donors in liver transplantation: a multicenter, randomized controlled trial—HOPExt

Correction: BMC Trials 24, 379 (2023)

https://doi.org/10.1186/s13063-023-07402-0

Following publication of the original article [1], we have been informed that Table 1 has been misaligned during typesetting.

Table 1.

Schedule of enrolment, interventions, and assessments in the HOPExt trial

STAGES	V1 Screening	V2 Inclusion			V3	V4	V5 –V11	V12	V13-V16
Time point Actions	At inscription for LT or at pre LT visit	D0 At hospitalization for LT	D0 HOPE group only		D0 + 6 h (± 2 h) after LT	D0 + 12 h (± 2 h) after LT	Day 1 to day 7 (± 1 day)	End of hospital stay	M3; M6: M9 and M12 (± 30 days)
Inclusion / non-inclusion criteria	X	X
Informed consent	X
Medical history and patient characteristics1	X
MELD score	X At inscription	X
Randomization2		X
Clinical examination3		X						X	X
Biological analyses4		X (before LT)			X	X	X	X	X
CHILD–PUGH score		X (before LT)
Donor characteristics5		X
HOPE perfusion parameters6			X
Bacteriological and fungal analyses7		X	X
Intra-operative data8		X
Liver Biopsy9		X both groups	X
Machine perfusate sample10			X
ICU and hospital stay								X
Morbidity (Clavien-Dindo Score, CCI)								X	X At M3 only
Concomitant Medication		X			X	X	X	X	X
Adverse events		X			X	X	X	X	X
Abdominal contrast enhanced MRI/MRCP									X At M12 only

¹patient characteristics: age, gender, height, weight, BMI, blood group, cause of cirrhosis, indication for transplantation, medical history (diabetes mellitus, arterial hypertension, transjugular intrahepatic portosystemic shunt) pretransplant status of residence (home, hospital ward or intensive care unit (ICU))

²Randomization will be performed after the harvesting team has macroscopically assessed the graft and confirmed that the graft will be harvested. After checking the inclusion and non-inclusion criteria an online randomization tool will be used. Randomization will be stratified by center and MELD score at the time of transplantation with a cut-off of 30

³Clinical examination: vital signs (temperature, blood pressure, heart rate), body weight, height, BMI

⁴Biological analyses: AST, ALT, GGT, Alkaline Phosphatase, bilirubin, factor V, INR, platelets, creatinine, GFR, lactates

At V2 only, a pregnancy test (beta HCG) will be done for women of childbearing age

⁵Donor characteristics: age, gender, height, weight, BMI, blood group, length of stay in intensive care unit, cause of death, occurrence of cardiac arrest, biological test (AST, ALT, natremia)

⁶Parameters measured during HOPE perfusion (only in HOPE group): perfusion pressure, flow, temperature, duration of machine perfusion, perfusate oxygenation (partial pressure O2) and CO2 content (partial pressure CO2) at the beginning and at the end of machine perfusion; perfusate AST and ALT, LDH, hyaluronic acid, lactate levels at 30 minutes and at the end of machine perfusion

⁷Bacteriological and fungal samplings will be taken on static storage solution (IGL-1) at the end of the back-table in both groups, and of the perfusion solution at the end of machine perfusion for HOPE group

⁸Intra-operative data: surgical technique of transplantation (piggy-back vs. vena cava resection), length of procedure, transfusion needs (fresh frozen plasma, red blood cell, thrombocyte concentrate), occurrence of post-reperfusion syndrome (decrease of 50% of the median arterial pressure during the 5 minutes after the revascularisation), cold ischemia time, circulatory support at the end of transplantation (noradrenaline (mg/h))

⁹A biopsy will be taken on the back-table before machine perfusion in both study groups, immediately after liver machine perfusion in the HOPE group, and after reperfusion of the liver in both groups

¹⁰3ml sample will be taken from machine perfusion solution during HOPE perfusion (only in HOPE group), at 30 minutes and at the end of machine perfusion

The original article has been corrected.